Pgi21 - Cost-Effectiveness Analysis of Ustekinumab Versus Adalimumab, Infliximab and Vedolizumab for the Treatment of Patients With Moderately to Severe Active Crohn’s Disease for Turkey

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.863
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost-Minimization Analysis of Infliximab Versus Adalimumab in the Treatment of Crohn’s Disease and Ulcerative Colitis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?

Digestive Diseases and Sciences
PhysiologyGastroenterology
2018English

Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2019English

Pgi22 - Cost-Effectiveness of Vedolizumab Versus Ustekinumab in United Kingdom Crohn's Disease Patients Who Previously Failed TNF Inhibitor Therapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Adalimumab for Endoscopic and Histopathological Mucosal Healing in Paediatric Patients With Moderate to Severe Crohn’s Disease

Przeglad Gastroenterologiczny
Gastroenterology
2017English

Psy114 - Cost-Effectiveness of Vedolizumab Compared With Conventional Therapy in Patients With Crohn’s Disease in the United Kingdom (Uk)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Utility Analysis of Infliximab and Adalimumab for Refractory Ulcerative Colitis

Cost Effectiveness and Resource Allocation
Health Policy
2009English

Subtherapeutic Concentrations of Infliximab and Adalimumab Are Associated With Increased Disease Activity in Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy